Corporate Citizenship is Our Highest Priority
Creating shared value is the guiding principle for how we do business. Shared value goes far beyond economic performance. It means doing the right thing, contributing to society, and making a positive impact in the community while ensuring the long-term success of our business. In short, it’s all about the company you keep. At Catalyst, corporate citizenship is based on the highest ethical standards and a strong desire to help underserved communities with the hope of improved patient outcomes and improved lives.
To achieve this goal, Catalyst created a corporate compliance program that will help reinforce, monitor, and verify that all of our employees and representatives adhere to our high ethical standards.
To report ethical concerns, ask questions, or seek guidance on Catalyst standards, please visit: www.catalystpharma.ethicspoint.com. Or contact our third-party hotline: United States: (844) 318-4121 Canada: (844) 543-8350
Committed to Quality Control and Patient Access
Medication should be safe, effective, and easy to use–that’s why Catalyst invested millions of dollars over 5 years to move closer to its goal of providing every patient access to a high-quality and easy-to-use product.
The focus of Catalyst’s clinical development program is to design a quality product that is backed by Good Manufacturing Practices (GMP). GMP is a system for ensuring that products are consistently produced and controlled according to a predetermined set of quality standards and that each step of the process is documented. The process helps to ensure that the highest-quality product is produced at all times, and it rigorously works to detect and resolve any potential quality, control issues.
The goal of GMP is to offer patients a high-quality product with every dose they take. With amifampridine, patients can be sure they are receiving the right dose every time. In 2017, amifampridine received orphan drug designation and Breakthrough Therapy designation from the FDA.
Every patient should have access to necessary medication—Catalyst is committed to efforts to make its products available to all patients regardless of their ability to pay.
One example of this is the Expanded Access Program (EAP) that we created for our lead product. Through the EAP, any patient in the United States, within the scope of allowed diagnoses, may access the product at no charge prior to FDA approval.
Catalyst is working with insurance companies to help optimize coverage for its FDA-approved products, as well as developing a support program for privately insured patients in need. For those patients who may be underinsured or uninsured, Catalyst plans to work with third-party support programs designed to help patients overcome any obstacles to obtaining our products.
Catalyst Pharmaceuticals is an organization based on strong values of responsibility and integrity. Our Code of Conduct contains general guidelines for conducting business with the highest standards of ethics.
See the EthicsPoint FAQs for more information.